Domestic Firm Joins Competitive Market for Anti-Hypertension Treatments

Published: 2005-01-20 06:58:00

Updated: 2005-01-20 06:58:00

The pharmaceutical industry expects an elevated level of competition in the domestic ARB (angiotensin II receptor blocker) hypertension treatment market currently predominated by foreign-invested firms, with an introduction of Olmetec (olmesartan medoxomil) by Daewoong Pharmaceutical.

Discove...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK